Terminal Instrument Approach Procedures (TERPS). In developing these SIAPs, the TERPS criteria were applied to the conditions existing or anticipated at the affected airports. Because of the close and immediate relationship between these SIAPs and safety in air commerce, I find that notice and public procedure before adopting these SIAPs are impracticable and contrary to the public interest and, where applicable, that good cause exists for making some SIAPs effective in less than 30 days.

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore—(1) is not a ''significant regulatory action'' under Executive Order 12866; (2) is not a ''significant rule'' under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. For the same reason, the FAA certifies that this amendment will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 97

Air traffic control, Airports, Navigation (air).

Issued in Washington, DC on September 4, 1998.

Richard O. Gordon,

Acting Director, Flight Standards Service.

Adoption of the Amendment

Accordingly, pursuant to the authority delegated to me, part 97 of the Federal Aviation Regulations (14 CFR part 97) is amended by establishing, amending, suspending, or revoking Standard Instrument Approach Procedures, effective at 0901 UTC on the dates specified, as follows:

PART 97—STANDARD INSTRUMENT APPROACH PROCEDURES

1. The authority citation for part 97 is revised to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120, 44701; and 14 CFR 11.49(b)(2).

2. Part 97 is amended to read as follows:

§§ 97.23, 97.25, 97.27, 97.29, 97.31, 97.33, 97.35 [Amended]

By amending: § 97.23 VOR, VOR/DME, VOR or TACAN, and VOR/DME or TACAN; § 97.25 LOC, LOC/DME, LDA, LDA/DME, SDF, SDF/DME; § 97.27 NDB, NDB/DME; § 97.29 ILS, ILS/DME, ISMLS, MLS, MLS/DME, MLS/RNAV; § 97.31 RADAR SIAPs; § 97.33 RNAV SIAPs; and § 97.35 COPTER SIAPs, identified as follows:

** * * Effective 8 October, 1998*

Tallahassee, FL, Tallahasse Regional, ILS RWY 27, Amdt 6
Greensboro, GA, Greene County Regional, LOC RWY 24, Orig
Greensboro, GA, Greene County Regional, NDB RWY 24, Orig
Boise, ID, Boise Air Terminal/Gowen Field, VOR/DME OR TACAN RWY 10L, Orig
Boise, ID, Boise Air Terminal/Gowen Field, NDB RWY 10L, Orig
Chicago, IL, Merrill C. Meigs, VOR/DME–A, Orig
De Kalb IL, De Kalb Taylor Muni, NDB RWY 27, Amdt 2, CANCELLED
De Kalb IL, De Kalb Taylor Muni, NDB RWY 27, Orig
Hawesville, KY, Hancock Airfield, NDB OR GPS–A, Amdt 6, CANCELLED
Hawesville, KY, Hancock Airfield, VOR OR GPS RWY 15, Amdt 6, CANCELLED
Hawesville, KY, Hancock Airfield, VOR RWY 33, Amdt 6, CANCELLED

** * * Effective 5 November, 1998*

Winfield/Arkansas, KS, Strother Field, VOR RWY 35, Orig–A, CANCELLED

** * * Effective 3 December, 1998*

Pueblo, CO, Pueblo Memorial, GPS RWY 8L, Orig
Pueblo, CO, Pueblo Memorial, GPS RWY 26R, Orig
Glenwood, MN, Glenwood Muni, VOR RWY 33, Amdt 2
Glenwood, MN, Glenwood Muni, GPS RWY 33, Orig
Slayton, MN, Slayton Muni, GPS RWY 35, Orig
Robbinsville, NJ, Trenton-Robbinsville, GPS RWY 11, Orig
Robbinsville, NJ, Trenton-Robbinsville, GPS RWY 29, Orig
Woodbine, NJ, Woodbine Muni, GPS RWY 19, Orig
Millbrook, NY, Sky Acres, VOR–A, Amdt 7
Millbrook, NY, Sky Acres, GPS RWY 17, Orig
Millbrook, NY, Sky Acres, GPS RWY 35, Orig
New Richmond, WI, New Richmond Muni, GPS RWY 32, Orig

Note: The FAA published the following amendment in Docket No. 29293, Amdt No. 1881 to Part 97 of the Federal Aviation Regulations (Volume 63, No. 152, Page 42225; dated Friday, August 7, 1998) under Section 97.23 effective October 8, 1998 which is hereby rescinded:

Camarillo, CA, Camarillo, VOR RWY 26, Amdt 5

[FR Doc. 98–24615 Filed 9–11–98; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 522 and 556

Animal Drugs, Feeds, and Related Products; Enrofloxacin Solution

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Bayer Corp., Agriculture Division, Animal Health. The NADA provides for subcutaneous use of enrofloxacin solution in cattle for the treatment of bovine respiratory disease.

EFFECTIVE DATE: September 14, 1998.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV–133), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1644.

SUPPLEMENTARY INFORMATION: Bayer Corp., Agriculture Division, Animal Health, P.O. Box 390, Shawnee Mission, KS 66201, has filed NADA 141–068 Baytril 100 Injectable Solution (100 milligrams enrofloxacin per milliliter) for subcutaneous injection for the treatment of cattle for bovine respiratory disease associated with *Pasteurella haemolytica*, *P. multocida*, and *Haemophilus somnus*. The NADA is approved as of July 24, 1998, and the regulations are amended by revising 21 CFR 522.812 to reflect the approval. The regulations are also amended to provide for a tolerance for enrofloxacin residues in cattle by revising 21 CFR 556.228. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval for food-producing animals qualifies for 3 years of marketing exclusivity beginning July 24, 1998, because the NADA contains substantial evidence of the effectiveness of the drug

involved, studies of animal safety or, in the case of food-producing animals, human food safety studies (other than bioequivalence or residue studies) required for approval and conducted or sponsored by the applicant.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

List of Subjects

21 CFR Part 522

Animal drugs.

21 CFR Part 556

Animal drugs, Foods.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 522 and 556 are amended as follows:

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

2. Section 522.812 is amended by revising paragraph (a), by redesignating paragraphs (d)(1), (d)(2), and (d)(3) as paragraphs (d)(1)(i), (d)(1)(ii), and (d)(1)(iii), respectively, by adding a new heading to paragraph (d)(1), and by adding paragraphs (c) and (d)(2) to read as follows:

§ 522.812 Enrofloxacin solution.

(a) *Specifications.* Each milliliter of sterile solution contains either 22.7 milligrams of enrofloxacin when intended for use in dogs or 100 milligrams of enrofloxacin when intended for use in cattle.

* * * * *

(c) *Related tolerance.* See § 556.228 of this chapter.

(d) *Conditions of use*—(1) *Dogs*—(i) *Amount.* * * *

* * * * *

(2) *Cattle*—(i) *Amount.* Single-dose therapy: 7.5 to 12.5 milligrams enrofloxacin per kilogram of body weight (3.4 to 5.7 milliliters per 100 pounds). Multiple-day therapy: 2.5 to 5.0 milligrams per kilogram of body weight (1.1 to 2.3 milliliters per 100 pounds) administered once daily for 3 to 5 days.

(ii) *Indications for use.* For the treatment of bovine respiratory disease (BRD) associated with *Pasteurella haemolytica, P. multocida,* and *Haemophilus somnus.*

(iii) *Limitations.* For subcutaneous use in cattle only. Do not inject more than 20 milliliters at each site. Do not slaughter within 28 days of last treatment. Do not use in cattle intended for dairy production. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. The effect of enrofloxacin on bovine reproductive performance, pregnancy, and lactation have not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

3. The authority citation for 21 CFR part 556 continues to read as follows:

Authority: 21 U.S.C. 342, 360b, 371.

4. Section 556.228 is amended by redesignating the text as paragraph (a), by adding a heading to the newly redesignated paragraph (a), and by adding an introductory text and paragraph (b) to read as follows:

§ 556.228 Enrofloxacin.

The acceptable daily intake for enrofloxacin is 3 micrograms per kilogram of body weight per day.

(a) *Chickens and turkeys.* * * *

(b) *Cattle.* A tolerance of 0.1 part per million for desethylene ciprofloxacin (marker residue) has been established in liver (target tissue) of cattle.

Dated: August 25, 1998.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 98–24497 Filed 9–11–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF DEFENSE

Office of the Secretary

32 CFR Part 234

Conduct on the Pentagon Reservation

AGENCY: Department of Defense.

ACTION: Final rule.

SUMMARY: This document makes administrative amendments to the Department of Defense rule on ''Conduct on the Pentagon Reservation''.

EFFECTIVE DATE: October 14, 1998.

FOR FURTHER INFORMATION CONTACT: L. Bynum or P. Toppings, 703/697–4111.

List of Subjects in 32 CFR Part 234

Alcohol abuse, Drug abuse, Drug testing, Federal buildings and facilities, Security measures, Traffic regulation.

Accordingly, 32 CFR Part 234 is amended as follows:

PART 234—[AMENDED]

1. The authority citation for part 234 continues to read as follows:

Authority: 10 U.S.C. 131 and 2674(c).

§ 234.1 [Amended]

2. Section 234.1, *Possession,* is amended by revising ''of dominion'' to read ''or dominion'' and *Weapons* by revising ''and bow'' to read ''any bow''.

§ 234.7 [Amended]

3. Section 234.7(e) is amended by removing the word ''which'' both times if appears.

§ 234.13 [Amended]

4. Sections 234.13(e) and 234.14 are amended by revising ''§ 234.4(d)'' to read ''§ 234.3(d)''.

§ 234.17 [Amended]

5. Section 234.17 is amended in paragraph (b)(3)(i) after the word trunk, by removing the word ''to''; paragraph (b)(3)(ii) by revising the semicolon to a period, paragraph (c)(1)(ii) first sentence by revising ''0.08 grams of'' to read ''0.08 grams or''; paragraphs (c)(2) and (c)(3)(i) by revising ''(b)(1)'' to read ''(c)(1)''; paragraph (c)(4) by revising ''(b)(1)(ii)'' read ''(c)(1)(ii)''; paragraph (c)(4)(ii) by revising ''paragraph (b)(4)(i)'' to read ''paragraphs (c)(3) and (c)(4)(i)'' and paragraph (c)(3)(ii) first sentence by adding the word ''to'' after ''submit.''

Dated: September 8, 1998.

L.M. Bynum,

Alternate OSD Federal Register Liaison, Department of Defense.

[FR Doc. 98–24547 Filed 9–11–98; 8:45 am]

BILLING CODE 5000–04–M